Latest Breaking News On - Cytokinetic executive vice president - Page 1 : comparemela.com

Royalty Pharma and Cytokinetics Announce Expanded Strategic

Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO,.

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

22.05.2024 - Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) - Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, . Seite 1

Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology

SOUTH SAN FRANCISCO, Calif., May 17, 2024 Cytokinetics, Incorporated announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium.

Cytokinetics To Host Muscle Seminar

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine